Investment Thesis
iRhythm demonstrates strong 26% revenue growth with exceptional 70.9% gross margins, but operational execution is severely lacking with -$16.2M operating losses and -$33.1M negative free cash flow despite scale. For a medical device company generating $199.4M in revenue with such favorable unit economics, profitability should be achievable—indicating either unsustainable spending or structural inefficiencies that require substantial correction.
Strengths
- Strong topline growth of 26.2% YoY in medical devices sector demonstrates market demand
- Exceptional gross margin of 70.9% indicates superior pricing power and cost structure
- Fortress balance sheet with $240.1M cash, low debt/equity of 0.22x, and 5.17x current ratio provides financial flexibility
Risks
- Operating losses of -$16.2M despite high gross margins—suggests excessive OpEx relative to revenue generation capability
- Negative free cash flow of -$33.1M and negative operating cash flow of -$26.2M indicate company is burning cash despite rapid growth
- Unprofitable on both net income (-$13.9M) and EPS (-$0.43) basis—path to profitability remains undefined and execution is questionable
Key Metrics to Watch
- Operating margin trajectory toward breakeven and positive profitability
- Operating cash flow inflection from negative to positive as revenue scales
- Operating expense growth rate relative to revenue growth rate—critical efficiency indicator
Financial Metrics
Revenue
199.4M
Net Income
-13.9M
EPS (Diluted)
$-0.43
Free Cash Flow
-33.1M
Total Assets
1.0B
Cash
240.1M
Profitability Ratios
Gross Margin
70.9%
Operating Margin
-8.1%
Net Margin
-7.0%
ROE
-8.6%
ROA
-1.4%
FCF Margin
-16.6%
Balance Sheet & Liquidity
Current Ratio
5.17x
Quick Ratio
4.98x
Debt/Equity
0.22x
Debt/Assets
84.0%
Interest Coverage
-4.92x
Long-term Debt
35.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T18:00:15.272111 |
Data as of: 2026-03-31 |
Powered by Claude AI